Document is current

Article History

Received: 14 September 2021

Accepted: 23 May 2022

First Online: 7 June 2022

Declarations

:

: In all countries where reference to an independent ethics committee (IEC) or institutional review board (IRB) is required, documented approval from appropriate IECs/IRBs will be obtained for all participating centers prior to study start. When necessary, an extension, amendment, or renewal of the IEC/IRB approval must be obtained and also forwarded to the study initiator and funder. The IEC/IRB must supply to the study initiator and funder, upon request, a list of the IEC/IRB members involved in the vote and a statement to confirm that the IEC/IRB is organized and operates according to applicable laws and regulations.Before documentation of any patient data, informed consent is obtained by the patient in writing. For patients under legal age, signed assent by the patient (where applicable) and parental/legal guardian signed informed consent will be obtained. Informed consent forms will be provided for persons who are capable to give their consent. For adult patients and for children not capable to give their consent, the legal representative should give the consent. In countries where required by law or regulation, the investigator must have the IEC/IRB written approval/favorable opinion of the written informed consent form(s) and any other written information to be provided to patients prior to the beginning of the observation.

: Not applicable.

: JCHY discloses consultancy or advisory roles for Boehringer Ingelheim, Novartis, AstraZeneca, Roche/Genentech, Clovis Oncology, Lilly, Merck Serono, Celgene, Astellas, Bayer, Pfizer, Ono Pharmaceutical, BMS, Yuhan, Hansoh, Blueprint Medicines, Daiichi Sankyo, G1 Therapeutics, AbbVie, Amgen, Takeda, and Incyte; travel/accommodation/expenses from Pfizer; honoraria from Boehringer Ingelheim, Roche, MSD, AstraZeneca, Novartis, BMS, Ono Pharmaceutical, Takeda, Lilly, and Pfizer.MSB discloses research support to the University of Pennsylvania School of Medicine from Bayer, Loxo Oncology, Genentech, Eisai, Blueprint Medicines, Lilly, and Novartis; consultancy for Bayer, Loxo Oncology, Genentech, AstraZeneca, and Lilly; and honoraria from Clinical Care Options, Medscape, OncLive, and PeerView.GC discloses travel/accommodation/expenses, honoraria, speaker bureau, and advisory roles for Bayer, and honoraria from Foundation Medicine.UNL discloses advisory board roles for Bayer, Pfizer, and Novartis; and research funding from BMS, GSK, Pfizer, and Roche.SL discloses an advisory role and travel grant support for Bayer.AP discloses personal fees from Bayer.FL-R discloses honoraria from BMS, Roche, Bayer, Lilly, AstraZeneca, Pfizer, MSD, and Thermo Fisher; and associated research funding paid to institution from BMS, Thermo Fisher, Roche, and Pfizer.JAR and MF are employees of Bayer.FP-L discloses advisory roles for Bayer, Roche, Illumina, and NanoString; and research grants paid to institution from Bayer, Roche, and NanoString.ERR discloses consultancy and advisory roles for Bayer.GT discloses advisory roles for AbbVie and Bayer; speaker fees from Medac and Novocure; research grants from Roche Diagnostics and Medac; an educational grant from Novocure; and travel grants from Novocure and Medac.GV discloses advisory roles for Bayer, Hutchison Pharma, Roche/Genentech, AstraZeneca, Pfizer, Ipsen, and BMS without personal remuneration.AD discloses honoraria/advisory board roles for Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Elevation Oncology; associated research paid to institution: Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, PharmaMar; research funding from Foundation Medicine; royalties: Wolters Kluwer; other: Merck – Food/Beverage, Puma – Food/Beverage, Merus – Food/Beverage, Boehringer Ingelheim; CME Honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Options.JT discloses consultancy roles for Bayer, Deciphera, Blueprint Medicines, Epizyme, and Daiichi Sankyo.ESK declares that he has no competing interests.